Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Drug development

Topic: Drug trials: efficacy and safety

Plain-language summary

Background Effective treatments for neurodegenerative disease remain elusive, highlighting the importance of prevention. Probucol, a lipid-lowering antioxidant, is neuroprotective in preclinical models but untested for dementia in large populations. Methods Using the Japan Medical Data Centre claims database (2014–2023), adults aged ≥ 50 years prescribed probucol or statins were identified. Propensity score matching produced a stacked cohort of 52,532 individuals. Conditional logistic regression estimated odds ratios (ORs) for incident all-cause dementia and subtypes, adjusted for age and sex; stratified Cox models accounted for follow-up time. Results Probucol use was associated with approximately 51% lower odds of all-cause dementia than statins combined (adjusted OR 0.48, 95% CI 0.45–0.53). Associations were consistent across statins (adjusted ORs 0.40–0.66), Alzheimer’s disease, and vascular dementia. Sensitivity analyses were comparable (adjusted HR 0.50, 95% CI 0.45–0.56). Conclusions In this nationwide cohort, probucol use was associated with substantially lower dementia risk than statins, supporting evaluation of probucol for repurposing in dementia prevention.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Takechi, R., Dunne, J., Lam, V., Stephan, B. M., Pereira, G., Clarnette, R., et al. (2026). Repurposing probucol for prevention of dementia: a nationwide cohort study. Research Square. https://doi.org/10.21203/rs.3.rs-10311061/v1

Vancouver

Takechi R, Dunne J, Lam V, Stephan BM, Pereira G, Clarnette R, et al. Repurposing probucol for prevention of dementia: a nationwide cohort study. Research Square. 2026. doi:10.21203/rs.3.rs-10311061/v1.

BibTeX

@article{takechi2026-25853c66,
  author  = {Takechi, R. and Dunne, J. and Lam, V. and Stephan, B. M. and Pereira, G. and Clarnette, R. and Watts, G. F. and Flicker, L. and others},
  title   = {{Repurposing probucol for prevention of dementia: a nationwide cohort study}},
  journal = {Research Square},
  year    = {2026},
  doi     = {10.21203/rs.3.rs-10311061/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-10311061/v1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 25 of the 62 points it could be judged on, which is 40 of 100. Raw total 40 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 40 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 40 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 62 points we could judge it on, which is 40 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (Research Square)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 4 / 4 52,532 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 25 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 25 of the 62 points we could judge it on is 40 out of 100.
Total 40 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also tagged “metabolic-syndrome”

306 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 306 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →